ログイン
ランキング
お知らせ
ログイン
文献詳細
総説
文献概要
はじめに
片頭痛は，悪心，嘔吐および光過敏や音過敏などを伴う，拍動性の著しい痛みを特徴とする日常生活に支障をきたすほどの頭痛である。中枢神経系におけるセロトニンの低下が基本的病態であり，セロトニンの5-HT1B/1D受容体アゴニストであるトリプタンが効果を示す。しかし一部にはトリプタンが有効性を示さない症例もあり，さらなる病態の解明およびトリプタンに代わる新しい片頭痛治療薬も必要とされている。本稿では片頭痛の最新の病態理論と仮説を解説するとともに，最近開発され海外で治験が進みつつある片頭痛新規治療薬であるカルシトニン遺伝子関連ペプチド（calcitonin gene-related peptide：CGRP）受容体アンタゴニストの効果について概説する。
片頭痛は，悪心，嘔吐および光過敏や音過敏などを伴う，拍動性の著しい痛みを特徴とする日常生活に支障をきたすほどの頭痛である。中枢神経系におけるセロトニンの低下が基本的病態であり，セロトニンの5-HT1B/1D受容体アゴニストであるトリプタンが効果を示す。しかし一部にはトリプタンが有効性を示さない症例もあり，さらなる病態の解明およびトリプタンに代わる新しい片頭痛治療薬も必要とされている。本稿では片頭痛の最新の病態理論と仮説を解説するとともに，最近開発され海外で治験が進みつつある片頭痛新規治療薬であるカルシトニン遺伝子関連ペプチド（calcitonin gene-related peptide：CGRP）受容体アンタゴニストの効果について概説する。
参考文献
1) Graham JR, Wolff HG: Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 39: 737-763, 1938
2) Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA et al: Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 28: 791-798, 1990
3) Leão AAP: Spreading depression of activity in the cerebral cortex. J Neurophysiol 78: 359-390, 1944
4) Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, et al: Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98: 4687-4692, 2001
5) Moskowitz MA: The neurobiology of vascular head pain. Ann Neurol 16: 157-168, 1984
6) Hanani M: Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain Res Rev 48: 457-476, 2005
7) Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, et al: Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47: 1008-1023, 2007
8) Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J: Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 8: 718-723, 2009
9) Damodaram S, Thalakoti S, Freeman SE, Garrett FG, Durham PL: Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 49: 5-20, 2009
10) Takeda M, Takahashi M, Matsumoto S: Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci Biobehav Rev 33: 784-792, 2009
11) Kristiansen KA, Edvinsson L: Neurogenic inflammation: a study of rat trigeminal ganglion. J Headache Pain 11: 485-495, 2010
12) Ceruti S, Villa G, Fumagalli M, Colombo L, Magni G, et al: Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain. J Neurosci 31: 3638-3649, 2011
13) Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, et al: Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 30: 8807-8814, 2010
14) Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, et al: Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 69: 855-865, 2011
15) Asghar MS, Hansen AE, Amin FM, van der Geest RJ, van der Koning P, et al: Evidence for a vascular factor in migrainef. Ann Neurol 69: 635-645, 2011
16) 独立行政法人医薬品医療機器総合機構ホームページ（http://www.info.pmda.go.jp/kouchishinsei/kouchishinsei index.html）
17) Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, et al: International Union of Pharmacology. XXXII. The mammalian calcitonin generelated peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54: 233-246, 2002
18) Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, et al: Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 507: 1277-1299, 2008
19) Levy D, Burstein R, Strassman AM: Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58: 698-705, 2005
20) Doods G, Hallermayer D, Wu M, Entzeroth M, Rudolf K, et al: Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129: 420-423, 2000
21) Villalón CM, Olesen J: The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124: 309-323, 2009
22) Iovino U, Feifel CL, Yong JM, Wolters JM, Wallenstein G: Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 24: 645-656, 2004
23) Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, et al: Calcitonin gene-related peptide receptor antagonist BIBN4096 BS for the acute treatment of migraine. N Engl J Med 350: 1104-1110, 2004
24) Williams TM, Stump CA, Nguyen DN, Quigley AG, Bell IM, et al: Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg Med Chem Lett 16: 2595-2598, 2006
25) Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, et al: Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372: 2115-2123, 2008
26) Dodick DW, Kost J, Assaid C, Lines C, Ho TW: Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia 31: 296-300, 2011
27) Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, et al: Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73: 970-977, 2009
28) Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, et al: Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 51: 73-84, 2011
29) Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, et al: Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31: 712-722, 2011
30) Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, et al: BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31: 573-584, 2011
掲載誌情報
